membranous neohropathy
Conditions
Interventions
RASI, finerenone and SGLT2I group:After receiving the maximum tolerated dose of ACEI/ARB for 4 weeks, the treatment was combined with finerenone and SGLT2i. The finerenone regimen was 10 mg orally, 1/
RASI, finerenone, SGLT2I and hydroxychloroquine group:After 4 weeks of ACEI/ARB treatment at the maximum tolerated dose, the treatment was combined with finerenone, SGLT2I and hydroxychloroquine
the finerenone regimen was 10 mg orally, 1/day for 26 weeks
the SGLT2i regimen was dapagliflozin 10 mg orally, 1/day for 26 weeks
and hydroxychloroquine regimen was 400 mg/day orally for 26 weeks in patients with a body weight of =50 kg and 300 mg/d orally in patients with a body weight of <50 kg for 26 weeks.
Sponsors
The First Affiliated Hospital of the People's Liberation Army Air Force University of Military Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Written informed consent is obtained; 2. Aged 18-80 years; 3. Patients diagnosed with idiopathic membranous nephropathy by renal biopsy and not converted to urine protein after 3-6 months of previous hormonal and immunosuppressive therapy. 4. eGFR =30 ml/min .1.73 m2, urine protein 30 g/L; 5. Blood potassium = 5 mmol/L;
Exclusion criteria
Exclusion criteria: 1. Presence of active infection or diagnosis of secondary membranous nephropathy; 2. Positive HBV serology (HBsAg or/and HBeAg or HBcAb), HCV positivity or abnormal liver function; 3. Diagnosis of diabetes mellitus or impaired glucose tolerance (2-hour postprandial blood glucose 7.8-11 mmol/L). 4. Have a clear history of peptic ulcer and/or gastrointestinal bleeding within the last six months 5. Have a congenital or acquired immunodeficiency, or with active tuberculosis and active cytomegalovirus infection, or with a severe infectious defect requiring intravenous antibiotic therapy 6. Suffering from serious cardiovascular diseases such as congenital heart disease, cardiac arrhythmia and heart failure; 7. Other serious physical or mental illness; 8. Pregnancy, contraceptive failure, or breastfeeding; 9. Hormones and immunosuppressants have been applied in the three months prior to enrolment; 10. Participation in other clinical trials within three months prior to enrolment; 11. Blood pressure = 90/60 mmHg; 12. Those who are allergic to hydroxychloroquine; 13. Those with eye diseases; 14. Those with heart block;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Random urine protein/creatinine(UACR);24-hour urine protein quantification; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum Phospholipase A2 Receptor Antibody(PLA2Rab);glycosylated hemoglobin(HbA1c%);routine urinalysis;Estimating glomerular filtration rate;kidney function;haemonium;blood lipid;blood glucose;blood counts;serum albumin; | — |
Countries
China
Contacts
Public ContactLijie He
The First Affiliated Hospital of the People's Liberation Army Air Force University of Military Medicine
Outcome results
None listed